Co-founder of Dermadis, Managing Director and Chief Scientific Officer. Dr. Kündig obtained his Ph.D in life sciences at Swiss Institute of Technology of Zurich, Switzerland. He joined Professor Marc Ouellette's laboratory at Laval University (Québec, Canada) in 1994 as post-doctoral fellow where he worked on drug resistance mechanisms of Leishmaniosis. He then joined Essential Therapeutics in Mountain View, California as Sr. Research Scientist focusing on the development of novel drug efflux pump inhibitors. Med Discovery hired Dr. Kündig to manage R&D at the beginning of its R&D activity in 2003 and he is currently Director of Manufacturing and R&D. Dr Kündig has a deep knowledge of biotherapeutic development from the discovery to clinical validation.
In October 2010, Sandra Ferreira joined the company Dermadis to support the management of administration and human resources. She had previously been an executive assistant in one of the largest investment fund in Geneva (Index Ventures) and in different societies as SpinX Technologies and Med Discovery. She has extensive experience in managing high-risk companies and the establishment of their administrative structure.
Dr. Deperthes obtained his Ph.D. in Molecular and Cellular Biology from Laval University in Canada in 1996. Discoverer of a new prostate cancer marker, the kallikrein KLK2, with Prof. Rolland R. Tremblay, he is an expert in kallikrein field. In 2000 he created and directed the Urology Research Unit (URU) at the Lausanne University Hospital, Lausanne, Switzerland.
In 2002, Dr. Deperthes founded Med Discovery SA within University of Lausanne before transferring Med Discovery SA in Geneva after the round A of financing in 2005. Since this time, he is CEO and Chairman of the Board and raised over Euro 10 million for Med Discovery SA. He is also an expert for WIPO (World Intellectual Property Organization) in Licensing and Business Innovation, and board member of Webster University research committee and jury member of Venturekick (foundation supporting innovation). Dr. Deperthes moved at the beginning of 2012 as Director of Business & Development and Licensing at Debiopharm, a mid-size Pharma. He remains President of Dermadis and he will use his network and knowledge in the biotech field to help Dermadis in licensing deal.
Patrick Dupuy, MD, has been appointed as Medical Director at Dermadis since April 2013. He is a dermatologist with an extensive background and experience of more than 20 years in research and drug development of medicinal products in the dermatology field. In 2002, he founded and developed with success the start-up company Orfagen, dedicated to orphan drugs. For the last 10 years, he has acquired a profound expertise in rare cutaneous diseases, like Netherton syndrome and many other conditions. He is recognized as an expert in this field, with impressive credentials at the international level.